Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EPS (Basic) (2020 - 2025)

Mirum Pharmaceuticals has reported EPS (Basic) over the past 6 years, most recently at -$0.12 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.12 for Q4 2025, up 75.51% from a year ago — trailing twelve months through Dec 2025 was -$0.48 (up 74.05% YoY), and the annual figure for FY2025 was -$0.47, up 74.59%.
  • EPS (Basic) for Q4 2025 was -$0.12 at Mirum Pharmaceuticals, down from $0.06 in the prior quarter.
  • Over the last five years, EPS (Basic) for MIRM hit a ceiling of $1.91 in Q4 2021 and a floor of -$1.94 in Q2 2023.
  • Median EPS (Basic) over the past 5 years was -$0.64 (2023), compared with a mean of -$0.66.
  • Biggest five-year swings in EPS (Basic): surged 232.64% in 2021 and later tumbled 151.31% in 2022.
  • Mirum Pharmaceuticals' EPS (Basic) stood at $1.91 in 2021, then tumbled by 151.31% to -$0.98 in 2022, then rose by 26.53% to -$0.72 in 2023, then surged by 31.94% to -$0.49 in 2024, then soared by 75.51% to -$0.12 in 2025.
  • The last three reported values for EPS (Basic) were -$0.12 (Q4 2025), $0.06 (Q3 2025), and -$0.12 (Q2 2025) per Business Quant data.